• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of patients suffering from depression. A customized treatment could be the solution.

Cue is an intervention platform for digital devices that transforms passively acquired smartphone sensor data into personalized micro-interventions that improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

deep depression treatment is among the world's leading causes of mental illness.1 Yet, only half of those suffering from the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to identify and treat patients with the highest chance of responding to specific treatments.

Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from specific treatments. They use mobile phone sensors and a voice assistant incorporating artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to discover biological and behavioral indicators of response.

To date, the majority of research on predictors for depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographics such as gender, age, and education, and clinical characteristics like symptom severity and comorbidities as well as biological markers.

Very few studies have used longitudinal data to predict mood in individuals. Many studies do not take into consideration the fact that mood varies significantly between individuals. It is therefore important to develop methods which allow for the analysis and measurement of individual differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify distinct patterns of behavior and emotions that vary between individuals.

The team also devised a machine learning algorithm to model dynamic predictors for the mood of each person's depression. The algorithm blends the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype has been associated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was not strong (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1 yet it is often untreated and not diagnosed. hormonal depression treatment disorders are usually not treated because of the stigma attached to them and the absence of effective interventions.

To aid in the development of a personalized home treatment for depression plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. The current prediction methods rely heavily on clinical interviews, which are not reliable and only detect a few features associated with depression treatment ect.

Machine learning can improve the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes collected from smartphone sensors along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes are able to capture a variety of distinct behaviors and activities that are difficult to document through interviews and permit high-resolution, continuous measurements.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment according to the degree of their depression. Patients with a CAT DI score of 35 65 students were assigned online support with an instructor and those with scores of 75 were sent to clinics in-person for psychotherapy.

Participants were asked a set of questions at the beginning of the study about their psychosocial and demographic characteristics as well as their socioeconomic status. These included age, sex and education, as well as work and financial status; if they were partnered, divorced or single; the frequency of suicidal ideation, intent or attempts; as well as the frequency with the frequency they consumed alcohol. Participants also rated their level of depression severity on a scale ranging from 0-100 using the CAT-DI. The CAT-DI assessment was performed every two weeks for participants who received online support and weekly for those who received in-person assistance.

Predictors of Treatment Reaction

The development of a personalized depression treatment is currently a top research topic and many studies aim at identifying predictors that enable clinicians to determine the most effective medication for each person. Particularly, pharmacogenetics can identify genetic variants that influence the way that the body processes antidepressants. This enables doctors to choose medications that are likely to be most effective for each patient, while minimizing the time and effort in trials and errors, while eliminating any side effects that could otherwise slow advancement.

Another approach that is promising is to build predictive models that incorporate the clinical data with neural imaging data. These models can be used to determine the variables that are most likely to predict a specific outcome, like whether a drug will improve mood or symptoms. These models can be used to determine the patient's response to a treatment, which will help doctors to maximize the effectiveness.

A new generation of studies employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been demonstrated to be useful in predicting outcomes of treatment, such as response to antidepressants. These techniques are becoming increasingly popular in psychiatry, and are likely to become the norm in the future medical practice.

In addition to prediction models based on ML, research into the mechanisms that cause depression is continuing. Recent findings suggest that the disorder is linked with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

Internet-delivered interventions can be a way to achieve this. They can provide an individualized and tailored experience for patients. One study found that an internet-based program improved symptoms and led to a better quality life for MDD patients. A randomized controlled study of an individualized treatment for depression found that a significant percentage of participants experienced sustained improvement and had fewer adverse consequences.

Predictors of Side Effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will have minimal or no side effects. Many patients are prescribed a variety medications before finding a medication that is effective and tolerated. Pharmacogenetics offers a fresh and exciting method to choose antidepressant medications that is more efficient and targeted.

There are a variety of variables that can be used to determine which antidepressant should be prescribed, such as gene variations, phenotypes of patients like gender or ethnicity and comorbidities. However it is difficult to determine the most reliable and reliable factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials of considerably larger samples than those typically enrolled in clinical trials. This is because the detection of interaction effects or moderators may be much more difficult in trials that only consider a single episode of treatment per patient instead of multiple sessions of treatment over a period of time.

Additionally the prediction of a patient's reaction to a particular medication will likely also need to incorporate information regarding the symptom profile and comorbidities, in addition to the patient's prior subjective experience with tolerability and efficacy. There are currently only a few easily measurable sociodemographic variables as well as clinical variables appear to be consistently associated with response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its infancy, and many challenges remain. First it is necessary to have a clear understanding of the underlying genetic mechanisms is required as well as a clear definition of what treatment for depression is a reliable indicator of treatment response. In addition, ethical issues such as privacy and the responsible use of personal genetic information must be carefully considered. The use of pharmacogenetics may be able to, over the long term, reduce stigma surrounding mental health treatments and improve the outcomes of treatment. But, like any other psychiatric treatment, careful consideration and implementation is necessary. At present, the most effective course of action is to offer patients various effective depression medications and encourage them to talk freely with their doctors about their experiences and concerns.